Microcap Ledger Korsana Biosciences, Inc. $KRSA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Waltham, MA
- Fiscal year end
- December 31
- Shares outstanding
- 4,681,351 [10-Q 2026-08-04]
What the company doesAI summary of filing
Korsana Biosciences (formerly Cyclerion) develops therapeutic candidates for neuropsychiatric disorders. The company's primary focus is CYC-126, an anesthetic-based therapy combining propofol and dexmedetomidine with a personalized delivery system for treatment-resistant depression, which it plans to advance to a Phase 2 proof-of-concept study in the second half of 2026. The company is pre-revenue and generates funding through licensing agreements with partners such as Akebia (which is advancing praliciguat for kidney disease) and through milestone payments; it also holds legacy soluble guanylate cyclase stimulator assets that were sold to or licensed to other parties. Korsana is seeking additional capital through equity financing to fund its clinical development programs. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $0.00 | −$4.93M | −$2.61M | $1.39M | [10-Q 2026-08-04] |
| FY ended Dec 2025 | $2.07M | −$3.53M | −$3.31M | $3.24M | [S-4/A 2026-07-22] |
| FY ended Dec 2024 | $2.00M | −$3.06M | −$4.33M | $3.23M | [S-4/A 2026-07-22] |
- Quarterly cash burn
- −$1.30M
- Cash runway Estimate
- ~3.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-09 | 2,710,096 | [10-Q 2024-11-14] |
| 2025-02-28 | 2,710,096 | [10-K/A 2025-11-12] |
| 2025-05-02 | 3,210,094 | [10-Q 2025-05-06] |
| 2025-08-01 | 3,337,436 | [10-Q 2025-08-05] |
| 2025-11-10 | 3,925,314 | [10-Q 2025-11-12] |
| 2026-03-26 | 4,330,314 | [10-K 2026-03-30] |
| 2026-05-08 | 4,330,314 | [10-Q 2026-05-12] |
| 2026-08-04 | 4,681,351 | [10-Q 2026-08-04] |
- Shelf registration
- S-3 filed 2025-05-06; declared effective 2025-05-15 [S-3 2025-05-06]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-14 | Chicko Rhonda M. | exercise | 25,000 | $2.35 | [4 2026-08-18] |
| 2026-08-14 | Graul Regina Margaret | exercise | 55,849 | $3.30 | [4 2026-08-18] |
| 2026-08-14 | Graul Regina Margaret | other | 48,629 | $3.79 | [4 2026-08-18] |
| 2026-07-16 | Hecht Peter M | other | 351,037 | — | [4 2026-07-20] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-07 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-10-05 | PRE 14A | Proxy statement |
| 2026-09-18 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-09-16 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-09-15 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-09-11 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-09-11 | 8-K | Material agreement entered; Acquisition or disposition completed; Results of operations |
| 2026-08-27 | 8-K | Shareholder vote results; Other events |
| 2026-08-25 | 8-K | Other events |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-04 | 10-Q | Quarterly report |
Alerts for $KRSA
Email me when Korsana Biosciences, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.